ReviewTrends in molecular medicine2018
Focus on Fundamentals: Achieving Effective Nanoparticle Targeting.
Review in Trends in molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05978791 (Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus), which is not on this map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on the Thrombolytic Effect of Platelet Membrane Coated Recombinant Staphylokinase on Human Arterial Thrombus
Who cites it
60 citing papers in PubMed.
- Advances in Cubosome-Based Transdermal Delivery: Structural Design, Manufacturing, and Engineering Strategies.ACS omega · 2026Review
- Advances in Bioactive Polysaccharide-Small-Molecule Drug Supramolecular Nanocomplexes for Drug Delivery and Therapeutic Applications.Journal of functional biomaterials · 2026Review
- Nanomaterials reshaping cancer radiotherapy: Radiosensitization mechanisms, delivery and theranostic platforms, multimodal synergy, and clinical translation strategies.Materials today. Bio · 2026Review
- cDC1 Subtype-Specific In Vivo Targeting of Liposomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Renoprotective actions of puerarin and the prospects of kidney-targeted nanodelivery.Frontiers in pharmacology · 2026Review
- Extracellular vesicle-based delivery to airway basal cells for durable gene therapy in cystic fibrosis.Frontiers in bioengineering and biotechnology · 2026Review
- Immunomodulatory Biomaterials for Bone and Soft Tissue Chronic Inflammation Diseases.Small science · 2025Review
- Chaperone nanomotors with chemotactic ability for the treatment of Parkinson's disease.Science advances · 2025Article
- Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Engineered hybrid cell membrane nanosystems for treating cardiovascular diseases.Materials today. Bio · 2025Review
- Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer.Science translational medicine · 2025Article
- Acoustic Field Enabled Polymeric Nanoparticle Deposition onto Vessel Walls for Enhanced Drug Delivery.Nano letters · 2025Article
- Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes.Nanomaterials (Basel, Switzerland) · 2025Review
- Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes.Pharmaceutics · 2025Review
- Review
- Nanoparticle-Based Drug Delivery for Vascular Applications.Bioengineering (Basel, Switzerland) · 2024Review
- Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.Journal of nanobiotechnology · 2024Review
- State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives.Pharmaceutics · 2024Review
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Nanoparticle-based T cell immunoimaging and immunomodulatory for diagnosing and treating transplant rejection.Heliyon · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Successful molecular targeting of nanoparticle drug carriers can enhance therapeutic specificity and reduce systemic toxicity. Typically, ligands specific for cognate receptors expressed on the intended target cell type are conjugated to the nanoparticle surface. This approach, often called active targeting, seems to imply that the conjugated ligand imbues the nanoparticle with homing capacity. However, ligand-receptor interactions are mediated by short-range forces and cannot produce magnetic-like attraction over larger distances. Successful targeting actually involves two key characteristics: contact of the nanoparticle with the intended target cell and subsequent ligand-mediated retention at the site. Here we propose a conceptual framework, based on recent literature combined with basic principles of molecular interactions, to guide rational design of nanoparticle targeting strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.